Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease
Habib, A., Minisi, A., Awad, M., Essa, A., Khalifa, A., Shehab-Eldeen, S. (2020). Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease. EKB Journal Management System, 5.1(1), 19-24. doi: 10.21608/mjvh.2020.125615
Alaa Habib; Ayman Minisi; Mahmoud Awad; Abdallah Essa; Amany Khalifa; Somaia Shehab-Eldeen. "Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease". EKB Journal Management System, 5.1, 1, 2020, 19-24. doi: 10.21608/mjvh.2020.125615
Habib, A., Minisi, A., Awad, M., Essa, A., Khalifa, A., Shehab-Eldeen, S. (2020). 'Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease', EKB Journal Management System, 5.1(1), pp. 19-24. doi: 10.21608/mjvh.2020.125615
Habib, A., Minisi, A., Awad, M., Essa, A., Khalifa, A., Shehab-Eldeen, S. Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease. EKB Journal Management System, 2020; 5.1(1): 19-24. doi: 10.21608/mjvh.2020.125615

Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease

Medical Journal of Viral Hepatitis
Article 5, Volume 5.1, Issue 1, November 2020, Page 19-24  XML PDF (783.45 K)
Document Type: Original article
DOI: 10.21608/mjvh.2020.125615
View on SCiNiTO View on SCiNiTO
Authors
Alaa Habib1; Ayman Minisi2; Mahmoud Awad2; Abdallah Essa3; Amany Khalifa4; Somaia Shehab-Eldeen5
1Internal Medicine dept, Faculty of Medicine, Mansoura Univ., Egypt.
2Internal Medicine, Faculty of Medicine, Mansura Univ., Egypt.
3Tropical Medicine, Faculty of Medicine, Menoufia Univ., Egypt
4Clinical Pathology, Faculty of Medicine, Menoufia Univ., Egypt.
5Tropical Medicine, Faculty of Medicine, Menoufia Univ., Egypt.
Abstract
Background: Inflammatory bowel disease (IBD) involves mainly Crohn’s disease (CD) and ulcerative colitis (UC). Distinguishing between the two dise-ases may be problematic in 15% of patients due to inconclusive findings on histopathology or endos-copy. miRNAs are non-coding RNAs composed of 18-23 nucleotides and are widely detected in the cells involved in variable pathological and physiological processes. The aim of this study is to assess if serum microRNA 106 and microRNA 223 (miR-223) can be reliable biomarkers in IBD patients. Methods: Serum levels of microRNA 106 and microRNA 223 (miR-223) were determined in 80 IBD patients by using the Transcript or First Stand cDNA, expression levels of serum miRNA in IBD patients and the control group and between active and inactive diseases were detected. Results: There was a significant increase in expression levels of serum miRNA 106 and miRNA 223 in IBD patients (UC and CD) compared to the control group (P<0.001, both). Also, There was a significant incr-ease of expression levels of serum miRNA 106 and serum miRNA 223 with increased disease activity of IBD (P <0.05, both). Conclusions: The levels of miRNA 106 and miRNA 223 are higher in the peripheral blood of IBD patients and the elevation is more significant in the active disease. The miRNA 106 and miRNA 223 may be used as a novel biomarker in the diagnosis of IBD and evaluating the disease activity.
Keywords
miRNA; inflammatory bowel disease; Crohn’s disease and ulcerative colitis
Statistics
Article View: 266
PDF Download: 487